Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

被引：1
|
作者：
Mok, T. S. K. [1 ]
Liu, G. [2 ]
Nyaw, S. F. [3 ]
Curcio, H. [4 ]
Cortot, A. [5 ]
Kam, T. Y. [6 ]
Descourt, R. [7 ]
Chik, Y. K. [8 ]
Cheema, P. K. [9 ]
Gwinnutt, J. M. [10 ]
Churchill, E. N. [11 ]
Nyborn, J. [12 ]
Curran, E. [13 ]
Yin, Y. [14 ]
Chong, K. [15 ]
Tanaka-Chambers, Y. [16 ]
Kretz, J. [17 ]
Cadranel, J. [18 ,19 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Princess Margaret Canc Ctr, Ontario Canc Inst, Med Oncol, Toronto, ON, Canada
[3] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Ctr Francois Baclesse, Oncol Dept, Caen, France
[5] CHRU Lille, Dept Thorac Oncol, Lille, France
[6] Pamela Youde Nethersole Eastern Hosp Main Block, Dept Clin Oncol, Hong Kong, Peoples R China
[7] CHU Brest, Oncol Dept, Hop Morvan, Brest, France
[8] Queen Elizabeth Hosp QEH, Dept Clin Oncol, Hong Kong, Peoples R China
[9] Univ Toronto, William Osler Hlth Syst, Oncol, Brampton, ON, Canada
[10] IQVIA, Global Epidemiol, Reading, Berks, England
[11] Takeda Pharmaceut USA Inc, Global Med Affairs Oncol, Lexington, MA USA
[12] Takeda Dev Ctr Amer Inc, Global Med Affairs Oncol, Cambridge, MA USA
[13] Takeda Dev Ctr Amer Inc, Global Evidence & Outcome Res, Lexington, MA USA
[14] Takeda Dev Ctr Amer Inc, Observat Res Analyt, Lexington, MA USA
[15] Takeda Dev Ctr Amer Inc, Clin Data Management, Cambridge, MA USA
[16] Takeda Pharmaceut, Stat & Quantitat Sci, Cambridge, MA USA
[17] Takeda Pharmaceut Int AG, Dept Thorac Oncol, Glattpark Opfikon, Zurich, Switzerland
[18] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, Paris, France
[19] Sorbonne Univ Paris, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585P
引用
收藏
页码：S1698 / S1699
页数：2
相关论文
共 50 条
  • [1] Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
    Liu, Geoffrey
    Nyaw, Shi Feng
    Mok, Tony S. K.
    Curcio, Hubert
    Cortot, Alexis B.
    Kam, Tsz Yeung
    Descourt, Renaud
    Chik, Yin Kwan
    Cheema, Parneet
    Gwinnutt, James M.
    Churchill, Eric N.
    Nyborn, Justin
    Curran, Eileen
    Savell, Alexandra
    Yin, Yu
    Chong, Katie
    Tanaka-Chambers, Yuka
    Kretz, Julian
    Cadranel, Jacques
    CANCER MEDICINE, 2025, 14 (03):
  • [2] Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
    Shi, Chao
    Xing, Ruyue
    Li, Mengmeng
    Feng, Junnan
    Sun, Rui
    Wei, Bing
    Guo, Yongjun
    Ma, Jie
    Wang, Huijuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations
    Christopoulos, Petros
    Prawitz, Thibaud
    Hong, Jin-Liern
    Lin, Huamao M.
    Hernandez, Luis
    Jin, Shu
    Tan, Min
    Proskorovsky, Irina
    Lin, Jianchang
    Zhang, Pingkuan
    Patel, Jyoti D.
    Ou, Sai-Hong I.
    Thomas, Michael
    Stenzinger, Albrecht
    LUNG CANCER, 2023, 179
  • [4] Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
    Dersarkissian, M.
    Bhak, R.
    Lin, H.
    Li, S.
    Cheng, M.
    Lax, A.
    Huang, H.
    Duh, M.
    Ou, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S681 - S681
  • [5] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Huanlan Sa
    Yan Shi
    Chunxia Ding
    Kewei Ma
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7729 - 7742
  • [6] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Sa, Huanlan
    Shi, Yan
    Ding, Chunxia
    Ma, Kewei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7729 - 7742
  • [7] Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
    Illini, Oliver
    Saalfeld, Felix Carl
    Christopoulos, Petros
    Duruisseaux, Michael
    Vikstroem, Anders
    Peled, Nir
    Demedts, Ingel
    Dudnik, Elizabeth
    Eisert, Anna
    Hashemi, Sayed M. S.
    Janzic, Urska
    Kian, Waleed
    Mohorcic, Katja
    Mohammed, Saara
    Silvoniemi, Maria
    Rothschild, Sacha I.
    Schulz, Christian
    Wesseler, Claas
    Addeo, Alfredo
    Armster, Karin
    Itchins, Malinda
    Ivanovic, Marija
    Kauffmann-Guerrero, Diego
    Koivunen, Jussi
    Kuon, Jonas
    Pavlakis, Nick
    Piet, Berber
    Sebastian, Martin
    Velthaus-Rusik, Janna-Lisa
    Wannesson, Luciano
    Wiesweg, Marcel
    Wurm, Robert
    Albers-Leischner, Corinna
    Aust, Daniela E.
    Janning, Melanie
    Fabikan, Hannah
    Herold, Sylvia
    Klimova, Anna
    Loges, Sonja
    Sharapova, Yana
    Schuetz, Maret
    Weinlinger, Christoph
    Valipour, Arschang
    Overbeck, Tobias Raphael
    Griesinger, Frank
    Jakopovic, Marko
    Hochmair, Maximilian J.
    Wermke, Martin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [8] Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
    Illini, O.
    Saalfeld, F. C.
    Christopoulos, P.
    Duruisseaux, M.
    Vikstrom, A.
    Peled, N.
    Demedts, I.
    Dudnik, E.
    Eisert, A.
    Hashemi, S. Ms
    Janzic, U.
    Kian, W.
    Mohorcic, K.
    Mohammed, S.
    Silvoniemi, M.
    Rothschild, S. I.
    Schulz, C.
    Wesseler, C.
    Addeo, A.
    Armster, K.
    Itchins, M.
    Ivanovic, M.
    Kauffmann-Guerrero, D.
    Koivunen, J.
    Kuon, J.
    Pavlakis, N.
    Piet, B.
    Sebastian, M.
    Velthaus-Rusik, J. -L.
    Wannesson, L.
    Wiesweg, M.
    Wurm, R.
    Albers-Leischner, C.
    Aust, D. E.
    Janning, M.
    Fabikan, H.
    Herold, S.
    Klimova, A.
    Loges, S.
    Sharapova, Y.
    Schuetz, M.
    Weinlinger, C.
    Lang-Stoeberl, A.
    Valipour, A.
    Overbeck, T. R.
    Griesinger, F.
    Jakopovic, M.
    Hochmair, M. J.
    Wermke, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S534 - S535
  • [9] Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer
    Huang, Wei-Sheng
    Li, Feng
    Gong, Yongjin
    Zhang, Yun
    Youngsaye, Willmen
    Xu, Yongjin
    Zhu, Xiaotian
    Greenfield, Matthew T.
    Kohlmann, Anna
    Taslimi, Paul M.
    Toms, Angela
    Zech, Stephan G.
    Zhou, Tianjun
    Das, Biplab
    Jang, Hyun G.
    Tugnait, Meera
    Ye, Yihua E.
    Gonzalvez, Francois
    Baker, Theresa E.
    Nadworny, Sara
    Ning, Yaoyu
    Wardwell, Scott D.
    Zhang, Sen
    Gould, Alexandra E.
    Hu, Yongbo
    Lane, Weston
    Skene, Robert J.
    Zou, Hua
    Clackson, Tim
    Narasimhan, Narayana I.
    Rivera, Victor M.
    Dalgarno, David C.
    Shakespeare, William C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [10] FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Duke, Elizabeth S.
    Stapleford, Liza
    Drezner, Nicole
    Amatya, Anup K.
    Mishra-Kalyani, Pallavi S.
    Shen, Yuan -Li
    Maxfield, Kimberly
    Zirkelbach, Jeanne Fourie
    Bi, Youwei
    Liu, Jiang
    Zhang, Xinyuan
    Wang, Hezhen
    Yang, Yuching
    Zheng, Nan
    Reece, Kelie
    Wearne, Emily
    Glen, Jacqueline J.
    Ojofeitimi, Idara
    Scepura, Barbara
    Nair, Abhilasha
    Bikkavilli, Rama Kamesh
    Ghosh, Soma
    Philip, Reena
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpeet
    Donoghue, Martha
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 508 - 512
12345